 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12...13141516171819202122232425» |
- Leukine (sargramostim) / Partner Therap
Enrollment closed: Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy (clinicaltrials.gov) - Jun 30, 2013
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
Trial completion, Combination therapy: Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer (clinicaltrials.gov) - Jun 25, 2013
P1, N=18, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer (clinicaltrials.gov) - Jun 24, 2013
P2, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=25 --> 48
- Leukine (sargramostim) / Partner Therap
New P1 trial: Leukine (Sargramostim) for Parkinson's Disease (clinicaltrials.gov) - Jun 18, 2013
P1, N=32, Recruiting, Sponsor: Howard Gendelman, MD
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 18, 2013
P1, N=14, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=25 --> 48 Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
Enrollment open, Combination therapy: Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS (clinicaltrials.gov) - Jun 13, 2013
P2, N=75, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Enrollment change: D9803: Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma (clinicaltrials.gov) - Jun 12, 2013
P3, N=702, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting N=518 --> 702
- Enrollment change: S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 11, 2013
P2, N=147, Active, not recruiting, Sponsor: Southwest Oncology Group
N=518 --> 702 N=99 --> 147
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination: MT2004-30: Tomotherapy for Solid Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=23, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
N=99 --> 147 Active, not recruiting --> Terminated; Replaced by another study
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: MT2004-30: Tomotherapy for Solid Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=23, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Terminated; Replaced by another study N=45 --> 23
- ||| Leukine (sargramostim) / Partner Therap, lorukafusp alfa (APN301) / Apeiron Biologics
Enrollment closed: Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Jun 10, 2013
P2, N=52, Active, not recruiting, Sponsor: Children's Oncology Group
N=45 --> 23 Suspended --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
New P1 trial: Sargramostim for Myeloid Dendritic Cell Deficiency (clinicaltrials.gov) - Jun 4, 2013
P1, N=15, Recruiting, Sponsor: Johns Hopkins University
- Leukine (sargramostim) / Partner Therap
Enrollment open: Sargramostim for Myeloid Dendritic Cell Deficiency (clinicaltrials.gov) - Jun 4, 2013
P1, N=15, Recruiting, Sponsor: Johns Hopkins University
Suspended --> Active, not recruiting Not yet recruiting --> Recruiting
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment change, Metastases: Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) - Jun 3, 2013
P2, N=42, Recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting N=110 --> 42
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment open, Metastases: Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) - Jun 3, 2013
P2, N=42, Recruiting, Sponsor: St. Jude Children's Research Hospital
N=110 --> 42 Not yet recruiting --> Recruiting
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
New P2 trial, Metastases: Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) - May 16, 2013
P2, N=42, Recruiting, Sponsor: St. Jude Children's Research Hospital
- Leukine (sargramostim) / Partner Therap
Trial termination: Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract (clinicaltrials.gov) - May 14, 2013
P2, N=7, Terminated, Sponsor: The University of Texas, Galveston
Not yet recruiting --> Recruiting Completed --> Terminated; Administratively Terminated
- Leukine (sargramostim) / Partner Therap
Trial termination, Combination therapy: Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer (clinicaltrials.gov) - May 14, 2013
P1, N=42, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Administratively Terminated Completed --> Terminated
- Leukine (sargramostim) / Partner Therap, Quadramet (samarium 153 lexidronam) / Jazz
Enrollment change, Metastases: 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer (clinicaltrials.gov) - May 9, 2013
P2, N=44, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated N=26 --> 44
- | Leukine (sargramostim) / Partner Therap
Enrollment change: COG-AOST0221: Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma (clinicaltrials.gov) - Apr 29, 2013
P2, N=49, Completed, Sponsor: Children's Oncology Group
N=26 --> 44 N=40 --> 49
- Leukine (sargramostim) / Partner Therap
Trial termination: Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Apr 22, 2013
P2, N=8, Terminated, Sponsor: M.D. Anderson Cancer Center
N=40 --> 49 Active, not recruiting --> Terminated; Slow Accrual
- Leukine (sargramostim) / Partner Therap
Enrollment change: Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Apr 22, 2013
P2, N=8, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; Slow Accrual N=40 --> 8
- Leukine (sargramostim) / Partner Therap, Herceptin (trastuzumab) / Roche
Enrollment closed: Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 22, 2013
P2, N=26, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=40 --> 8 Recruiting --> Active, not recruiting
- | Trial completion: Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma (clinicaltrials.gov) - Apr 16, 2013
P3, N=170, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma (clinicaltrials.gov) - Apr 10, 2013
P1/2, N=50, Completed, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial termination, Metastases: Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus (clinicaltrials.gov) - Apr 9, 2013
P2, N=0, Terminated, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Completed --> Terminated
- pegylated liposomal doxorubicin / Generic mfg.
Trial completion: Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 9, 2013
P1, N=48, Completed, Sponsor: University of Alabama at Birmingham
Completed --> Terminated Active, not recruiting --> Completed
- Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Clinical: WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation (clinicaltrials.gov) - Apr 7, 2013
P=N/A, N=20, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- |||||||||| Leukine (sargramostim) / Partner Therap
New P3 trial, Biopsy: Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma (clinicaltrials.gov) - Apr 7, 2013
P3, N=380, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- | Campath (alemtuzumab) / Sanofi, Rituxan (rituximab) / Roche
Enrollment closed: Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Apr 7, 2013
P2, N=42, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
Enrollment closed: Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant (clinicaltrials.gov) - Mar 28, 2013
P2, N=10, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
Trial completion: Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer (clinicaltrials.gov) - Mar 20, 2013
P2, N=40, Completed, Sponsor: Cancer Treatment Centers of America
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Leukine (sargramostim) / Partner Therap
Enrollment change, Metastases: Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma (clinicaltrials.gov) - Mar 18, 2013
P2, N=82, Completed, Sponsor: University of California, Irvine
Active, not recruiting --> Completed N=60 --> 82
- |||| Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma (clinicaltrials.gov) - Mar 18, 2013
P2, N=82, Completed, Sponsor: University of California, Irvine
N=60 --> 82 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change: GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 3, 2013
P2, N=14, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed N=29 --> 14
- IMA950 / Immatics, University Hospitals of Geneva
Enrollment closed: CRUK-CR0902-11: Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Mar 3, 2013
P1, N=45, Active, not recruiting, Sponsor: Cancer Research UK
N=29 --> 14 Completed --> Active, not recruiting
- mitomycin / Generic mfg., mitoxantrone / Generic mfg.
Trial completion: Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia (clinicaltrials.gov) - Feb 28, 2013
P1, N=29, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Completed --> Active, not recruiting Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
Enrollment open: Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax (clinicaltrials.gov) - Feb 13, 2013
P2, N=300, Recruiting, Sponsor: Jarrod P. Holmes, MD, FACP
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Leukine (sargramostim) / Partner Therap
Trial termination: Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 12, 2013
P1, N=0, Terminated, Sponsor: Columbia University
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Departure of PI
- UV1 / Ultimovacs
New P1/2 trial: A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. (clinicaltrials.gov) - Feb 7, 2013
P1/2, N=21, Recruiting, Sponsor: Oslo University Hospital
- UV1 / Ultimovacs
New P1/2 trial, Metastases: A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer (clinicaltrials.gov) - Feb 4, 2013
P1/2, N=21, Recruiting, Sponsor: Oslo University Hospital
- Trial termination: p53 Vaccine for Ovarian Cancer (clinicaltrials.gov) - Jan 29, 2013
P2, N=21, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Departure of PI Completed --> Terminated
- Leukine (sargramostim) / Partner Therap
Trial completion: Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Jan 23, 2013
P1/2, N=32, Completed, Sponsor: Robert Dreicer MD
Completed --> Terminated Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Enrollment change: Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma (clinicaltrials.gov) - Jan 14, 2013
P1, N=6, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=16 --> 6
- Leukine (sargramostim) / Partner Therap
Enrollment change: Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 14, 2013
P1, N=1, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=16 --> 6 N=70 --> 1
- Torisel (temsirolimus) / Pfizer, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
New P2 trial: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (clinicaltrials.gov) - Jan 10, 2013
P2, N=74, Suspended, Sponsor: National Cancer Institute (NCI)
- | daunorubicin / Generic mfg.
Enrollment change: Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia (clinicaltrials.gov) - Jan 9, 2013
P3, N=657, Active, not recruiting, Sponsor: Eastern Cooperative Oncology Group
N=70 --> 1 N=830 --> 657
- Leukine (sargramostim) / Partner Therap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment change, Combination therapy: MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jan 7, 2013
P2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
N=830 --> 657 N=30 --> 24
- Leukine (sargramostim) / Partner Therap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Combination therapy: MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jan 7, 2013
P2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
N=30 --> 24 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial initiation date: FAMPAP: Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP) (clinicaltrials.gov) - Jan 6, 2013
P2, N=2, Enrolling by invitation, Sponsor: Children's Hospital Medical Center, Cincinnati
Active, not recruiting --> Completed Initiation date: Nov 2011 --> Aug 2012